title: Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
abstract: OBJECTIVE
  A let-7 microRNA-complementary site (LCS6) polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression. We evaluated the LCS6 genotype and its association with KRAS mutation status, clinicopathologic features, and disease-free survival (DFS) in patients with stage III colon cancer who enrolled in a phase III clinical trial (NCCTG N0147).
  
  
  METHODS
  The LCS6 genotype was assayed by real-time PCR in DNA extracted from whole blood (n = 2,834) and compared with paired tumor tissue (n = 977). χ(2) and two-sample t tests were used to compare baseline factors and KRAS mutation status between patients defined by LCS6 variant status. Log-rank tests and multivariate Cox models assessed associations between LCS6 status and DFS, respectively.
  
  
  RESULTS
  We identified 432 (15.2%) blood samples and 143 (14.6%) tumor samples heterozygous or homozygous for the LCS6 G-allele, and 2,402 of 2,834 (84.8%) blood samples and 834 of 977 (85.4%) tumor samples homozygous for the LCS6 T-allele. Genotype results were highly concordant (99.8%) in cases with paired blood and tumor tissue (n = 977). G-allele carriers were significantly more frequent in Caucasians versus other races (χ(2) test, P < 0.0001). The LCS6 genotype was not associated with KRAS mutation status, clinicopathologic features (all P > 0.2), or DFS (log-rank P = 0.49; HR, 0.929; 95% confidence interval, 0.76-1.14), even after combining LCS6 genotype with KRAS mutation status.
  
  
  CONCLUSIONS
  In the largest association study investigating the LCS6 polymorphism in colon cancers, the germline LCS6 genotype was not associated with KRAS mutation status or with clinical outcome in patients with stage III tumors.
authors.affiliation: Authors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, ChinaAuthors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Sha
authors.affiliation: Authors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, China.
authors.forename: Adam M
authors.initials: AM
authors.lastname: Lee
authors.affiliation: Authors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Shi
authors.affiliation: Authors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, China.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Alberts
authors.affiliation: Authors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, China.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Sargent
authors.affiliation: Authors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, ChinaAuthors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, China.
authors.forename: Frank A
authors.initials: FA
authors.lastname: Sinicrope
authors.affiliation: Authors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, ChinaAuthors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, China Diasio.Robert@mayo.edu.
authors.forename: Robert B
authors.initials: RB
authors.lastname: Diasio
mesh_terms: D020413:3' Untranslated Regions / Q000235:genetics*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001665:Binding Sites; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D015996:Survival Rate; D055815:Young Adult; D018631:ras Proteins / Q000235:genetics*
chemical_list: D020413:3' Untranslated Regions; C117307:KRAS protein, human; D035683:MicroRNAs; D011518:Proto-Oncogene Proteins; C487931:mirnlet7 microRNA, human; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins
references.citation: Cancer Res. 2005 Aug 15;65(16):7065-70
references.pmid: 16103053
references.citation: Pharmacogenomics J. 2010 Oct;10(5):458-64
references.pmid: 20177422
references.citation: Carcinogenesis. 2009 Jun;30(6):1003-7
references.pmid: 19380522
references.citation: Biol Pharm Bull. 2006 May;29(5):903-6
references.pmid: 16651716
references.citation: Gut. 2012 Jun;61(6):847-54
references.pmid: 22427238
references.citation: Nature. 2004 Sep 16;431(7006):350-5
references.pmid: 15372042
references.citation: JAMA. 2012 Apr 4;307(13):1383-93
references.pmid: 22474202
references.citation: N Engl J Med. 2008 Oct 23;359(17):1757-65
references.pmid: 18946061
references.citation: J Clin Oncol. 2013 Oct 10;31(29):3664-72
references.pmid: 24019539
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Cell. 2005 Mar 11;120(5):635-47
references.pmid: 15766527
references.citation: Pharmacogenet Genomics. 2013 Mar;23(3):142-7
references.pmid: 23324806
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Cancer Res. 2004 Jun 1;64(11):3753-6
references.pmid: 15172979
references.citation: Nat Genet. 2002 Apr;30(4):363-4
references.pmid: 11896390
references.citation: BMC Cancer. 2012 Nov 20;12:534
references.pmid: 23167843
references.citation: Cell Cycle. 2008 Mar 15;7(6):759-64
references.pmid: 18344688
references.citation: Clin Cancer Res. 2011 Dec 15;17(24):7723-31
references.pmid: 21994416
references.citation: Lancet Oncol. 2011 Apr;12(4):377-86
references.pmid: 21435948
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: Nature. 2005 Jun 9;435(7043):834-8
references.pmid: 15944708
references.citation: Ann Surg Oncol. 2010 Jun;17(6):1471-4
references.pmid: 20180029
references.citation: Mod Pathol. 2013 Jun;26(6):825-34
references.pmid: 23348904
references.citation: Carcinogenesis. 2012 May;33(5):1046-54
references.pmid: 22331473
references.citation: J Biol Chem. 1990 Mar 15;265(8):4718-21
references.pmid: 2307682
references.citation: Cancer Res. 2008 Oct 15;68(20):8535-40
references.pmid: 18922928
references.citation: Lung Cancer. 2010 Jul;69(1):51-3
references.pmid: 19854534
references.citation: Nature. 2007 Jun 28;447(7148):1130-4
references.pmid: 17554337
references.citation: Cell. 2005 Dec 16;123(6):1133-46
references.pmid: 16337999
references.citation: Ann Oncol. 2011 Jan;22(1):104-109
references.pmid: 20603437
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Clin Cancer Res. 2012 Jun 15;18(12):3487-8; author reply 3489
references.pmid: 22669132
references.citation: J Clin Oncol. 2006 May 10;24(14):2179-87
references.pmid: 16682737
references.citation: Mod Pathol. 2011 Aug;24(8):1090-100
references.pmid: 21516079
references.citation: Clin Cancer Res. 2011 Jun 1;17(11):3742-50
references.pmid: 21385923
references.citation: Br J Cancer. 2009 Aug 18;101(4):715-21
references.pmid: 19603018
references.citation: Semin Oncol. 2011 Aug;38(4):500-10
references.pmid: 21810509